Skip to main content
SpringerLink
Log in

History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world

  • Clinical Review
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Hepatitis B virus (HBV) replication has been shown to persist at low levels in the liver for decades, even in patients with resolved HBV infection. In these cases, reactivation of HBV and ensuing hepatitis during or after cytotoxic or immunosuppressive therapy is now recognized as de novo HBV-related hepatitis. The occurrence of de novo HBV-related hepatitis has become more frequent after the introduction of rituximab for the treatment of hematological disorders, such as malignant lymphomas. More alarmingly, reactivation can lead to fatal fulminant hepatic failure, indicating a need to establish guidelines to prevent the occurrence of de novo HBV-related hepatitis. It is possible that lamivudine prophylaxis and close surveillance of serum HBV DNA are effective in this regard. However, such measures are currently not available to hepatitis B surface antigen (HBsAg)-negative patients in Japan. A preliminary guideline for preventing HBV reactivation during and after cytotoxic or immunosuppressive therapies was made in 2008 by two collaborative study groups from the Japanese Ministry of Health, Labour, and Welfare, including measures not only for HBV carriers, but also for patients with resolved HBV infection. Since this recommendation is a tentative one, further testing and improvements are being planned.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.

    Article  CAS  PubMed  Google Scholar 

  2. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–45.

    Article  CAS  PubMed  Google Scholar 

  3. Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol. 1987;126:492–9.

    Article  CAS  PubMed  Google Scholar 

  4. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104–8.

    Article  CAS  PubMed  Google Scholar 

  5. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology. 1998;27:1377–82.

    Article  CAS  PubMed  Google Scholar 

  6. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172–9.

    Article  CAS  PubMed  Google Scholar 

  7. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.

    Article  CAS  PubMed  Google Scholar 

  8. Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med. 2006;45:747–8.

    Article  PubMed  Google Scholar 

  9. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.

    Article  CAS  PubMed  Google Scholar 

  10. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.

    CAS  PubMed  Google Scholar 

  11. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182–8.

    Article  CAS  PubMed  Google Scholar 

  12. Dhedin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, et al. Reverse seroconversion of hepatitis B after allogenic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation. 1998;66:616–9.

    Article  CAS  PubMed  Google Scholar 

  13. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogenic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616–9.

    Article  PubMed  Google Scholar 

  14. Seth P, Alrajhi AA, Kagevi I, Chaudhary MA, Colcol E, Sahovic E, et al. Hepatitis B virus reactivation with clinical flare in allogenic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30:189–94.

    Article  CAS  PubMed  Google Scholar 

  15. Chen PM, Fan S, Liu CJ, Hsieh RK, Liu JH, Chuang MW, et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation. 1990;49:708–13.

    Article  CAS  PubMed  Google Scholar 

  16. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogenic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:925–9.

    Article  CAS  PubMed  Google Scholar 

  17. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  CAS  PubMed  Google Scholar 

  18. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–76.

    Article  CAS  PubMed  Google Scholar 

  19. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68–9.

    Article  CAS  PubMed  Google Scholar 

  20. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma. 2005;46:1085–9.

    Article  PubMed  Google Scholar 

  21. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005;11:189–91.

    Article  PubMed  Google Scholar 

  22. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006;45:721–4.

    Article  PubMed  Google Scholar 

  23. Tsutsumi Y, Tanaka J, Kawamura T, Kawamura T, Miura T, Kanamori H, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann Hematol. 2004;83:58–60.

    Article  CAS  PubMed  Google Scholar 

  24. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102:1930.

    Article  CAS  PubMed  Google Scholar 

  25. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.

    Article  CAS  PubMed  Google Scholar 

  26. Liu CJ, Kao JH, Chen DS. Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. Gastroenterology. 2006;131:1656. Author reply-7.

    Article  PubMed  Google Scholar 

  27. Douglas DD, Rakela J, Taswell HF, Krom RA, Wiesner RH. Hepatitis B virus replication patterns after orthotopic liver transplantation: de novo versus recurrent infection. Transplant Proc. 1993;25:1755–7.

    CAS  PubMed  Google Scholar 

  28. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation. 1998;65:494–9.

    Article  CAS  PubMed  Google Scholar 

  29. Rokuhara A, Tanaka E, Yagi S, Mizokami M, Hashikura Y, Kawasaki S, et al. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol. 2000;62:471–8.

    Article  CAS  PubMed  Google Scholar 

  30. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997;113:1668–74.

    Article  CAS  PubMed  Google Scholar 

  31. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation. 1997;64:1582–4.

    Article  CAS  PubMed  Google Scholar 

  32. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation. 1995;59:230–4.

    Article  CAS  PubMed  Google Scholar 

  33. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585–9.

    Article  CAS  PubMed  Google Scholar 

  34. Umemura T, Tanaka E, Kiyosawa K, Kumada H. The Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52–6.

    Article  PubMed  Google Scholar 

  35. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported in part by a Grants-in-Aid from the Ministry of Health, Labour, and Welfare of Japan and Viral Hepatitis Research Foundation of Japan.

Author information

Authors and Affiliations

  1. Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan

    Eiji Tanaka & Takeji Umemura

Authors
  1. Eiji Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeji Umemura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eiji Tanaka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tanaka, E., Umemura, T. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clin J Gastroenterol 1, 83–86 (2008). https://doi.org/10.1007/s12328-008-0030-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-008-0030-3

Keywords

Search

Navigation